Business Context and Reporting Period
Company: Passage BIO, Inc. (PASG)
Filing Type: Form 8-K (Current Report)
Date of Report: April 28, 2026
Context: The Company is reviewing strategic alternatives to maximize shareholder value. As part of this review, it announced a significant workforce restructuring plan on the date of this filing.
Key Financial Metrics
This filing does not provide comprehensive financial statements (revenue, profit, cash flow, or margins) for the period. The primary financial disclosure relates to restructuring costs:
- Estimated Restructuring Costs: Approximately $3.3 million in aggregate severance and exit costs.
- Timing of Expense Recognition: Costs are expected to be recorded primarily in the second quarter of 2026.
- Workforce Reduction: Approximately 75% of the workforce.
- Liquidity/Debt: The filing text does not provide clear values for current cash balances, debt levels, or liquidity metrics.
Material Changes
The material change reported is the initiation of a Restructuring Plan to decrease operating expenses. This involves a drastic reduction in headcount (75%) and the incurrence of one-time exit costs. The implementation is expected to be substantially complete during the second and third quarters of 2026.
Guidance, Outlook, and Risks
Management Commentary: The restructuring is a direct response to the ongoing review of strategic alternatives. Severance benefits are contingent upon employees executing and not revoking severance agreements that include a general release of claims.
Risks and Contingencies:
- Cost Variability: Actual costs may differ materially from the $3.3 million estimate due to assumptions and unforeseen events.
- Strategic Review Uncertainty: There is a risk that no suitable strategic alternative will be identified or consummated.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ from expectations regarding termination benefits and the financial impact of the restructuring.
Investor Verification Checklist
- Verify the exact number of employees impacted by the 75% reduction to assess operational capacity.
- Monitor the Company's cash burn rate and liquidity position in light of the $3.3 million immediate cash outflow for severance.
- Track the progress of the strategic alternatives review to determine if a transaction (e.g., merger, acquisition, sale) materializes.
- Review subsequent filings for any adjustments to the estimated $3.3 million restructuring cost.